Trends in Gynecologic Cancer Care in North America

Obstetrics and Gynecology Clinics of North America

Volumn 39, Issue 2, 2012, Pages 107-129

  Reade, Clare ^a,b   Elit, Laurie ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Outcomes; Processes; Quality of care; Structures

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TAXANE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DRUG EFFECT; EVIDENCE BASED MEDICINE; GYNECOLOGIC CANCER; GYNECOLOGIC CARE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; NORTH AMERICA; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREND STUDY; UTERINE CERVIX CANCER; VULVA CANCER;

CANADA; FEMALE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGY; HEALTH CARE COSTS; HEALTHCARE DISPARITIES; HUMANS; INSURANCE, HEALTH; MEXICO; MIDDLE AGED; NORTH AMERICA; QUALITY OF HEALTH CARE;

EID: 84861496389     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2012.02.003     Document Type: Review

References (99)

1. The WHO agenda WHO, Accessed August 5, 2011. http://www.who.int/about/agenda/en.index.html.
2. OECD reviews of health systems: Mexico 2005, OECD, OECD Publishing, Paris, Accessed October 11, 2011. http://www.oecdbookshop.org/oecd/display.asp?langEN&sf1identifiers&st1812005081e1.
3. Ruelas E. Health care quality improvement in Mexico: challenges, opportunities, and progress. Proc Bayl Univ Med Cent 2002, 15(3):319-322.
4. Frequently requested data OECD Health Data 2011, Accessed August 10, 2011. http://www.oecd.org/health/healthdata.
5. Public Information Accessed August 5, 2011. http://www.health.gov.on.ca/en/ministry/.
6. Glynn P.A. Timely and appropriate access to healthcare. The way forward-the roles of the players. Healthc Q 2006, 9(4):30-36. 32.
7. DeNavas C., Proctor B., Smith J. Income, poverty, and health insurance coverage in the United States. Current population reports 2010, United States Census Bureau, Washington, DC, Accessed October 11, 2011. http://www.census.gov/prod/2011pubs/p60-239.pdf.
8. Boukus E.R., Cunningham P.J. Mixed signals: trends in Americans' access to medical care, 2007-2010. Track Rep 2011, (25):1-6.
9. Tandon Ajay, Murray C.J., Lauer J.A., et al. Measuring overall health system performance for 191 countries. GPE Discussion Paper Series No. 30. 2000 Accessed October 11, 2011. http://www.who.int/healthinfo/paper30.pdf.
10. Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966, 44(3 Suppl):166-206.
11. Birkmeyer J.D., Dimick J.B., Birkmeyer N.J. Measuring the quality of surgical care: structure, process, or outcomes?. J Am Coll Surg 2004, 198(4):626-632.
12. Hillner B.E., Smith T.J., Desch C.E. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000, 18(11):2327-2340.
13. Elit L., Schultz S., Prysbysz R., et al. Patterns of care in the initial management of women with vulvar cancers in Ontario. Eur J Gynaecol Oncol 2009, 30(5):503-505.
14. Elit L., Schultz S., Prysbysz R., et al. Patterns of care for the initial management of cervical cancer in Ontario. Eur J Gynaecol Oncol 2009, 30(5):493-496.
15. Elit L., Schultz S., Prysbysz R., et al. Patterns of surgical care for uterine cancers in Ontario. Eur J Gynaecol Oncol 2009, 30(3):255-258.
16. Elit L., Schultz S., Prysbysz R., et al. Patterns of care in the initial management of women with ovarian cancer in Ontario. Eur J Gynaecol Oncol 2009, 30(4):361-364.
17. Ferlay J., Shin H., Bray F., et al. GLOBOCAN 2008 v1.2, Cancer incidence and Mortality Worldwide: IARC CancerBase No. 10 Accessed August 17, 2011. http://globocan.iarc.fr.
18. Cancer incidence in five continents 1966, Union Internationale Contre le Cancer, Geneva, No. I. R. Doll, P. Payne, J.A.H. Waterhouse (Eds.).
19. Howlader N., Noone A., Krapcho M., et al. SEER Cancer statistics review, 1975-2008 Bethesda, MD: National Cancer Institute, Accessed September 30, 2011. http://seer.cancer.gov/csr/1975_2008/index.html.
20. Engel J., Eckel R., Schubert-Fritschle G., et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002, 38(18):2435-2445.
21. Buys S.S., Partridge E., Black A., et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011, 305(22):2295-2303.
22. Brewster W.R. The complexity of race in the disparate outcome and treatment of minority patients. Gynecol Oncol 2008, 111(2):161-162.
23. Harlan L.C., Clegg L.X., Trimble E.L. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003, 21(18):3488-3494.
24. Farley J.H., Tian C., Rose G.S., et al. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer 2009, 115(18):4210-4217.
25. Terplan M., Temkin S., Tergas A., et al. Does equal treatment yield equal outcomes?. The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol 2008, 111(2):173-178.
26. Bristow R.E., Zahurak M.L., Ibeanu O.A. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol 2011, 121(2):364-368.
27. Elit L., Chartier C., Oza A., et al. Outcomes for systemic therapy in women with ovarian cancer. Gynecol Oncol 2006, 103(2):554-558.
28. Marth C., Hiebl S., Oberaigner W., et al. Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology. Int J Gynecol Cancer 2009, 19(1):94-102.
29. Stockton D., Davies T. Multiple cancer site comparison of adjusted survival by hospital of treatment: an East Anglian study. Br J Cancer 2000, 82(1):208-212.
30. Olaitan A., Weeks J., Mocroft A., et al. The surgical management of women with ovarian cancer in the south west of England. Br J Cancer 2001, 85(12):1824-1830.
31. Carney M.E., Lancaster J.M., Ford C., et al. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol Oncol 2002, 84(1):36-42.
32. Elit L., Bondy S.J., Paszat L., et al. Outcomes in surgery for ovarian cancer. Gynecol Oncol 2002, 87(3):260-267.
33. Grossi M., Quinn M.A., Thursfield V.J., et al. Ovarian cancer: patterns of care in Victoria during 1993-1995. Med J Aust 2002, 177(1):11-16.
34. Kumpulainen S., Grenman S., Kyyronen P., et al. Evidence of benefit from centralised treatment of ovarian cancer: a nationwide population-based survival analysis in Finland. Int J Cancer 2002, 102(5):541-544.
35. Cress R.D., O'Malley C.D., Leiserowitz G.S., et al. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol 2003, 21(8):1530-1535.
36. Ioka A., Tsukuma H., Ajiki W., et al. Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer. Cancer Sci 2004, 95(3):233-237.
37. Diaz-Montes T.P., Zahurak M.L., Giuntoli R.L., et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol 2005, 99(2):352-357.
38. Bailey J., Murdoch J., Anderson R., et al. Stage III and IV ovarian cancer in the South West of England: five-year outcome analysis for cases treated in 1998. Int J Gynecol Cancer 2006, 16(Suppl 1):25-29.
39. Earle C.C., Schrag D., Neville B.A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006, 98(3):172-180.
40. Engelen M.J., Kos H.E., Willemse P.H., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006, 106(3):589-598.
41. Goff B.A., Matthews B.J., Wynn M., et al. Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol 2006, 103(2):383-390.
42. Goff B.A., Matthews B.J., Larson E.H., et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 2007, 109(10):2031-2042.
43. Kumpulainen S., Kuoppala T., Leminen A., et al. Surgical treatment of ovarian cancer in different hospital categories-a prospective nation-wide study in Finland. Eur J Cancer 2006, 42(3):388-395.
44. Kumpulainen S., Sankila R., Leminen A., et al. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer-a prospective nation-wide study in Finland. Gynecol Oncol 2009, 115(2):199-203.
45. Oberaigner W., Stuhlinger W. Influence of department volume on cancer survival for gynaecological cancers-a population-based study in Tyrol, Austria. Gynecol Oncol 2006, 103(2):527-534.
46. Paulsen T., Kjaerheim K., Kaern J., et al. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006, 16(Suppl 1):11-17.
47. Schrag D., Earle C., Xu F., et al. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst 2006, 98(3):163-171.
48. Elit L.M., Bondy S.J., Paszat L.P., et al. Surgical outcomes in women with ovarian cancer. Can J Surg 2008, 51(5):346-354.
49. Bristow R.E., Zahurak M.L., Diaz-Montes T.P., et al. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol 2009, 115(3):334-338.
50. Vernooij F., Heintz A.P., Coebergh J.W., et al. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol 2009, 112(3):455-461.
51. Hershman D., Fleischauer A.T., Jacobson J.S., et al. Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. Gynecol Oncol 2004, 92(1):293-299.
52. Maas H.A., Kruitwagen R.F., Lemmens V.E., et al. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 2005, 97(1):104-109.
53. Petignat P., de Weck D., Goffin F., et al. Long-term survival of patients with apparent early-stage (FIGO I-II) epithelial ovarian cancer: a population-based study. Gynecol Obstet Invest 2007, 63(3):132-136.
54. Chan J., Fuh K., Shin J., et al. The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?. Br J Cancer 2008, 98(7):1191-1196.
55. Fairfield K.M., Lucas F.L., Earle C.C., et al. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population. Cancer 2010, 116(20):4840-4848.
56. Sundararajan V., Hershman D., Grann V.R., et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002, 20(1):173-178.
57. Petignat P., Fioretta G., Verkooijen H.M., et al. Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol 2004, 13(4):181-186.
58. Thrall M.M., Gray H.J., Symons R.G., et al. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol 2011, 122(1):100-106.
59. Vercelli M., Capocaccia R., Quaglia A., et al. Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group. Crit Rev Oncol Hematol 2000, 35(3):161-179.
60. Gronlund B., Hogdall C., Hansen H.H., et al. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 2002, 94(7):1961-1967.
61. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997, 80(7):1273-1283.
62. Bristow R.E., Tomacruz R.S., Armstrong D.K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20(5):1248-1259.
63. Chemotherapy for advanced ovarian cancer. Cochrane Database Syst Rev 2000, (2). Advanced Ovarian Cancer Trialists Group, CD001418.
64. Vergote I., Trope C.G., Amant F., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010, 363(10):943-953.
65. Fast Stats: An interactive tool for access to SEER cancer statistics 2011, Surveillance Research Program, National Cancer Institute, Accessed October 11, 2011. http://seer.cancer.gov/faststats.
66. Randall T.C., Armstrong K. Differences in treatment and outcome between African-American and white women with endometrial cancer. J Clin Oncol 2003, 21(22):4200-4206.
67. Tammemagi C.M. Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes. Curr Opin Obstet Gynecol 2007, 19(1):31-36.
68. Crawford S.C., De Caestecker L., Gillis C.R., et al. Staging quality is related to the survival of women with endometrial cancer: a Scottish population based study. Deficient surgical staging and omission of adjuvant radiotherapy is associated with poorer survival of women diagnosed with endometrial cancer in Scotland during 1996 and 1997. Br J Cancer 2002, 86(12):1837-1842.
69. Truong P.T., Kader H.A., Lacy B., et al. The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol 2005, 28(2):157-164.
70. Chan J.K., Wu H., Cheung M.K., et al. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 2007, 106(2):282-288.
71. Diaz-Montes T.P., Zahurak M.L., Giuntoli R.L., et al. Concentration of uterine cancer surgical care among the elderly: a population-based perspective. Gynecol Oncol 2007, 107(3):436-440.
72. Kwon J.S., Carey M.S., Cook E.F., et al. Patterns of practice and outcomes in intermediate- and high-risk stage I and II endometrial cancer: a population-based study. Int J Gynecol Cancer 2007, 17(2):433-440.
73. Kwon J.S., Carey M.S., Cook E.F., et al. Are there regional differences in gynecologic cancer outcomes in the context of a single-payer, publicly-funded health care system?. A population-based study. Can J Public Health 2008, 99(3):221-226.
74. Kitchener H., Swart A.M., Qian Q., et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009, 373(9658):125-136.
75. Creasman W.T., Mutch D.E., Herzog T.J. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid?. Gynecol Oncol 2010, 116(3):293-294.
76. Lee T.S., Kim J.W., Seong S.J., et al. Benefit of lymphadenectomy in endometrial cancer: can the truth be obtained by randomized controlled trial after ASTEC?. Int J Gynecol Cancer 2009, 19(8):1467.
77. Blake P., Swart A.M., Orton J., et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009, 373(9658):137-146.
78. Benedetti Panici P., Basile S., Maneschi F., et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008, 100(23):1707-1716.
79. Kong A., Simera I., Collingwood M., et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol 2007, 18(10):1595-1604.
80. Finn O.J., Edwards R.P. Human papillomavirus vaccine for cancer prevention. N Engl J Med 2009, 361(19):1899-1901.
81. Nieminen P., Kallio M., Anttila A., et al. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999, 83(1):55-58.
82. Canadian consensus guidelines on human papillomavirus. J Obstet Gynaecol Can 2007, 28(8 Suppl 3):S5-S6. HPV Consensus Guidelines Committee.
83. Brooks S.E., Chen T.T., Ghosh A., et al. Cervical cancer outcomes analysis: impact of age, race, and comorbid illness on hospitalizations for invasive carcinoma of the cervix. Gynecol Oncol 2000, 79(1):107-115.
84. Downs L.S., Smith J.S., Scarinci I., et al. The disparity of cervical cancer in diverse populations. Gynecol Oncol 2008, 109(2 Suppl):S22-S30.
85. Leath C.A., Straughn J.M., Kirby T.O., et al. Predictors of outcomes for women with cervical carcinoma. Gynecol Oncol 2005, 99(2):432-436.
86. Patel D.A., Barnholtz-Sloan J.S., Patel M.K., et al. A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: analysis of Surveillance, Epidemiology, and End Results data. Gynecol Oncol 2005, 97(2):550-558.
87. Morgan M.A., Behbakht K., Benjamin I., et al. Racial differences in survival from gynecologic cancer. Obstet Gynecol 1996, 88(6):914-918.
88. Downs L.S., Scarinci I., Einstein M.H., et al. Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol 2010, 117(3):486-490.
89. Webb J.C., Key C.R., Qualls C.R., et al. Population-based study of microinvasive adenocarcinoma of the uterine cervix. Obstet Gynecol 2001, 97(5 Pt 1):701-706.
90. Denton A.S., Bond S.J., Matthews S., et al. National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993. Clin Oncol (R Coll Radiol) 2000, 12(6):347-353.
91. Downing A., Mikeljevic J.S., Haward B., et al. Variation in the treatment of cervical cancer patients and the effect of consultant workload on survival: a population-based study. Eur J Cancer 2007, 43(2):363-370.
92. Pearcey R., Miao Q., Kong W., et al. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. J Clin Oncol 2007, 25(17):2383-2388.
93. Judson PL H.E., Baxter N.N., Durham S.B., et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006, 107(5):1018-1022.
94. Al-Ghamdi A., Freedman D., Miller D., et al. Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 Cases. Gynecol Oncol 2002, 84(1):94-101.
95. Hampl M., Deckers-Figiel S., Hampl J.A., et al. New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 2008, 109(3):340-345.
96. Rad S., Ogunyemi D. An analysis of the demographics and outcome of vulvar cancer in California. Gynecol Oncol 2007, 105(3):828-829.
97. Falconer A.D., Hirschowitz L., Weeks J., et al. The impact of improving outcomes guidance on surgical management of vulval squamous cell cancer in southwest England (1997-2002). BJOG 2007, 114(4):391-397.
98. Heaps J.M., Fu Y.S., Montz F.J., et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990, 38(3):309-314.
99. Multidisciplinary Cancer Conferences, Accessed October 26, 2011. https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=8256.